Sanofi registers Phase 2b trial of duvakitug in hidradenitis suppurativa, recruiting
Sanofi's dose-ranging "AURALIGHT" study of duvakitug in moderate to severe hidradenitis suppurativa is recruiting, with primary results expected by mid-2028.
Sanofi has one hidradenitis suppurativa trial update to report this week.
- NCT07812116, a Phase 2b trial of duvakitug (also known as SAR447189) in adults with moderate to severe hidradenitis suppurativa, is listed as recruiting. The study is a parallel, Phase 2b, 3-arm, double-blind, randomized, multicenter, multinational, placebo-controlled, dose-ranging study to evaluate the efficacy and the safety of different doses of duvakitug in adult participants with moderate to severe hidradenitis suppurativa1, sponsored by Sanofi with Teva Branded Pharmaceutical Products R&D LLC as a collaborator. The study began on 2026-10-19 and is estimated to enroll 156 participants, with the primary outcome measuring the percentage of participants achieving Hidradenitis Suppurativa Clinical Response 75 (HiSCR75), defined as a 75% or greater reduction from baseline in the total abscess and inflammatory nodule count, with no increase from baseline in abscess or draining tunnel count1, assessed at Week 16. Primary completion is estimated for 2028-06-16.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.